Related Experiment Video
Updated: Apr 30, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
Published on: May 18, 2018
Theanine improves the function of dendritic cells via the downregulation of cyclooxygenase-2 expression
Mingsheng Lei1, Jianhong Zuo2, Min Li3
1Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Department of Respiratory and Critical Care Medicine, Zhangjiajie City Hospital, Zhangjiajie, Hunan 427000, China.
Background:
Tumor cells can reduce the number of dendritic cells (DCs) in the tumor environment and cause DC dysfunction through autocrine or paracrine pathways. We sought to measure cyclooxygenase-2 (COX-2) expression in bombesin-inhibited DCs treated with theanine in vitro and to explore the protection and activation effects of theanine on DCs.
Methods:
Enzyme-linked immunosorbent assay (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and Western blotting were used to analyze the effects of theanine on COX-2 expression and interleukin (IL)-12/IL-10 secretion of bombesin-treated DCs.
Results:
DCs acquired an impaired phenotype as a result of bombesin treatment. Theanine increased the expression of mature DC surface molecules. The number of cell apoptosis with the treatment of bombesin and theanine significantly decreased, accounting for 15.9%, compared with 26.1% of cell apoptosis with bombesin. COX-2 expression in bombesin-treated DCs was inhibited by theanine in a dose-dependent manner. Theanine promoted DC secretion of IL-12. IL-12 levels reached (137.4 ± 4.9) pg/ml with theanine at 200 µmol/L. However, theanine inhibited the secretion of IL-10 in a dose-dependent manner. IL-10 levels were only (58.4 ± 6.9) pg/ml with theanine at 200 µmol/L.
Conclusion:
Theanine inhibits the transcription and translation of COX-2 and regulates the balance of IL-10/IL-12 secretion in bombesin-inhibited DCs, leading to the recovery of a state of activation in DCs.
Insights
Theanine protects dendritic cells (DCs) from tumor-induced dysfunction by inhibiting COX-2 expression and restoring a balanced IL-10/IL-12 secretion, promoting DC activation.
Area of Science:
- Immunology
- Cancer Biology
- Pharmacology
Background:
- Tumor cells impair dendritic cell (DC) function and number in the tumor microenvironment.
- Bombesin treatment in vitro induces DC dysfunction and apoptosis.
Purpose of the Study:
- To investigate the effects of theanine on cyclooxygenase-2 (COX-2) expression in bombesin-inhibited DCs.
- To evaluate the protective and activating effects of theanine on DCs.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA)
- Reverse transcription-polymerase chain reaction (RT-PCR)
- Western blotting analysis of COX-2 expression and IL-12/IL-10 secretion in DCs.
Main Results:
- Theanine treatment reduced DC apoptosis from 26.1% to 15.9%.
- Theanine dose-dependently inhibited COX-2 expression and promoted IL-12 secretion while suppressing IL-10 secretion in bombesin-treated DCs.
- Theanine enhanced the expression of mature DC surface molecules.
Conclusions:
- Theanine inhibits COX-2 transcription and translation in DCs.
- Theanine rebalances IL-10/IL-12 secretion, restoring DC activation.
- Theanine demonstrates potential in counteracting tumor-induced DC dysfunction.
Related Concept Videos
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
GPCRs Regulate Adenylyl Cylase Activity
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
